Dashboard
Manage Tickers

ATRSANTARES PHARMA, INC.

Nasdaq www.antarespharma.com


$ 5.59 $ 0.00 (0 %)    

Monday, 23-May-2022 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ 1.60 (0.35 %)
DIA $ 398.57 $ 0.56 (0.14 %)
SPY $ 530.36 $ 1.78 (0.34 %)
TLT $ 91.26 $ -0.13 (-0.14 %)
GLD $ 225.37 $ -0.50 (-0.22 %)
$ 5.59
$ 5.59 x 1,100
$ 5.62 x 2,000
-- - --
$ 3.11 - $ 5.60
2,707,496
na
950.88M
$ 1.77
$ 14.37
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2022 03-31-2022 10-Q
2 03-03-2022 12-31-2021 10-K
3 11-04-2021 09-30-2021 10-Q
4 08-05-2021 06-30-2021 10-Q
5 05-06-2021 03-31-2021 10-Q
6 03-02-2021 12-31-2020 10-K
7 11-05-2020 09-30-2020 10-Q
8 08-06-2020 06-30-2020 10-Q
9 05-05-2020 03-31-2020 10-Q
10 03-03-2020 12-31-2019 10-K
11 11-05-2019 09-30-2019 10-Q
12 08-06-2019 06-30-2019 10-Q
13 05-02-2019 03-31-2019 10-Q
14 03-12-2019 12-31-2018 10-K
15 11-06-2018 09-30-2018 10-Q
16 08-07-2018 06-30-2018 10-Q
17 05-08-2018 03-31-2018 10-Q
18 03-13-2018 12-31-2017 10-K
19 11-07-2017 09-30-2017 10-Q
20 08-08-2017 06-30-2017 10-Q
21 05-09-2017 03-31-2017 10-Q
22 03-14-2017 12-31-2016 10-K
23 11-09-2016 09-30-2016 10-Q
24 08-09-2016 06-30-2016 10-Q
25 05-09-2016 03-31-2016 10-Q
26 03-08-2016 12-31-2015 10-K
27 11-05-2015 09-30-2015 10-Q
28 08-10-2015 06-30-2015 10-Q
29 05-11-2015 03-31-2015 10-Q
30 03-12-2015 12-31-2014 10-K
31 11-06-2014 09-30-2014 10-Q
32 08-07-2014 06-30-2014 10-Q
33 05-09-2014 03-31-2014 10-Q
34 03-13-2014 12-31-2013 10-K
35 11-06-2013 09-30-2013 10-Q
36 08-07-2013 06-30-2013 10-Q
37 05-08-2013 03-31-2013 10-Q
38 03-13-2013 12-31-2012 10-K
39 11-07-2012 09-30-2012 10-Q
40 08-08-2012 06-30-2012 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

looking-into-antares-pharmas-return-on-invested-capital
Looking Into Antares Pharma's Return On In...
06/08/2022 13:55:36

Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million,...

Core News & Articles
Halozyme Reports Tender Offer To Buy All S...
04/26/2022 12:15:21

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned su...

benzingas-top-ratings-upgrades-downgrades-for-april-14-2022
Benzinga's Top Ratings Upgrades, Downgrade...
04/14/2022 14:03:32

Upgrades

looking-into-antares-pharma-incs-recent-short-interest
Looking Into Antares Pharma Inc's Recent S...
04/14/2022 13:14:48

Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. The company recently report...

truist-securities-downgrades-antares-pharma-to-hold-lowers-price-target-to-56
Truist Securities Downgrades Antares Pharm...
04/14/2022 11:54:30

Truist Securities analyst Gregory Fraser downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Hold and lowers the price targe...

ladenburg-thalmann-downgrades-antares-pharma-to-neutral
Ladenburg Thalmann Downgrades Antares Phar...
04/14/2022 11:52:06

Ladenburg Thalmann analyst Matthew Kaplan downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Neutral.

raymond-james-downgrades-antares-pharma-to-market-perform
Raymond James Downgrades Antares Pharma to...
04/14/2022 11:23:41

Raymond James analyst Elliot Wilbur downgrades Antares Pharma (NASDAQ:ATRS) from Strong Buy to Market Perform.

hc-wainwright--co-downgrades-antares-pharma-to-neutral-announces-56-price-target
HC Wainwright & Co. Downgrades Antares Pha...
04/14/2022 10:06:43

HC Wainwright & Co. analyst Oren Livnat downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Neutral and announces $5.6 p...

piper-sandler-downgrades-antares-pharma-to-neutral-lowers-price-target-to-56
Piper Sandler Downgrades Antares Pharma to...
04/14/2022 09:02:35

Piper Sandler analyst David Amsellem downgrades Antares Pharma (NASDAQ:ATRS) from Overweight to Neutral and lowers the price...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
04/13/2022 17:35:51

Gainers

why-antares-pharma-stock-is-soaring-today
Why Antares Pharma Stock Is Soaring Today
04/13/2022 14:40:12

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozy...

benzingas-daily-brief-on-trending-tickers-for-april-13-2022-jpmorgan-paypal-bed-bath--beyond-and-more
Benzinga's Daily Brief On Trending Tickers...
04/13/2022 13:28:39

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro plat...

the-daily-biotech-pulse-glaxosmithkline-and-halozyme-go-shopping-mylans-insulin-glargine-recall-turning-point-shares-lung-cancer-data-and-more
The Daily Biotech Pulse: GlaxoSmithKline A...
04/13/2022 12:15:53

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty...

morning-brief-top-stories-dominating-financial-media-on-wednesday-april-13
Morning Brief: Top Stories Dominating Fina...
04/13/2022 11:57:46

Reuters Blackrock To Introduce Its First China ETF In 2022: Reuters

halozyme-buys-antares-in-960m-deal-to-create-one-drug-delivery-specialty-product-entity
Halozyme Buys Antares In $960M Deal To Cre...
04/13/2022 11:43:51

Core News & Articles
Halozyme To Acquire Antares Pharma For $5....
04/13/2022 10:02:35

SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and An...

Core News & Articles
Wall Street Journal Reported Halozyme Ther...
04/13/2022 09:10:24

https://www.wsj.com/articles/halozyme-therapeutics-nears-deal-to-buy-antares-pharma-11649840401#:~:text=Halozyme%20would%20pay%...

antares-pharmas-oral-testosterone-treatment-scores-fda-approval
Antares Pharma's Oral Testosterone Treatme...
03/29/2022 15:43:47

the-daily-biotech-pulse-sanofi-igm-ink-antibody-drug-collaboration-neogenomics-sinks-on-ceo-departure-q1-warning-decision-day-for-akebia
The Daily Biotech Pulse: Sanofi-IGM Ink An...
03/29/2022 11:41:44

Here's a roundup of top developments in the biotech space over the last 24 hours:

Core News & Articles
UPDATE: Lipocine Sees Commercial Launch Of...
03/29/2022 11:06:52

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION